


WHAT IS MS?

Multiple sclerosis (MS) is a complex neurodegenerative disease affecting approximately 50,000 of the 37.9 million people in Poland.¹

Each person will experience this unpredictable disease differently, but common symptoms include pain, fatigue, reduced mobility and cognitive dysfunction.

There is currently no cure for MS; however, optimal treatment and support have a significant effect on disease progression and quality of life for people with MS.



PAIN



FATIGUE



REDUCED MOBILITY



COGNITIVE DYSFUNCTION

COUNTRY CONTEXT



Healthcare in Poland is organised by the Ministry of Health at the municipal, county and district level. The country spends €1,507 per person on health, which is lower than the European average.² Care is very fragmented but improvement initiatives are underway.



COUNTRY RANKING



HOW DOES POLAND SCORE COMPARED TO OTHER COUNTRIES?

(All countries are evaluated on a 0-100 scale)



WHAT DID THE BAROMETER FIND?



Poland has made recent improvements in MS care, which include expanding access to disease-modifying drugs and paediatric MS care. However, gaps in care remain:

20–29%
OF PEOPLE WITH MS HAVE ANNUAL ACCESS TO ESSENTIAL PHYSICAL REHABILITATION.



Only 20–29% of people with MS have annual access to essential physical rehabilitation.

0
REIMBURSEMENT FOR MANY SYMPTOMATIC TREATMENTS




There is zero reimbursement for many symptomatic treatments, including for fatigue and pain.

LONG
WAIT TO ACCESS DMDS



After diagnosis, people with MS must often wait many months to access disease-modifying drugs.



POLICY RECOMMENDATIONS

Develop a national neurological disease plan that includes a comprehensive approach to MS, with an adequate budget for implementation.



Ensure each person with MS receives multidisciplinary care including assessments for rehabilitation, psychiatric and social support each year.

Ensure that each person with MS has adequate reimbursement and timely access to all available disease-modifying drugs and symptomatic treatments in a timely manner.



More information can be found at www.emsp.org or contact biuro@ptrs.org.pl

EMSP would like to thank the sponsors which have financially supported this project including Almirall, Biogen, Bristol Myers Squibb, MedDay, Merck, Mylan, Novartis, Roche, and Sanofi Genzyme. EMSP retains editorial control of the Barometer.

